Intravitreal bevacizumab in the surgical treatment of proliferative diabetic retinopathy

Retina Today

Volumn , Issue MARCH, 2008, Pages 50-53

  Avery, Robert L ^a  

^a California Retina Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951125409     PISSN: None     EISSN: 18250572     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab treatment. Retina. 2006;26(3):352-354.
2. ®) for Retinal Vascular Diseases. Presented at: Annual Meeting of the American Academy of Ophthalmology; Chicago, Ill.; October 15, 2005.
3. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695.
4. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab in the surgical treatment of proliferative diabetic retinopathy. Presented at: Annual Meeting of the American Society of Retina Specialists; December 3, 2007; Palm Springs, CA.
5. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213-216.